Cargando…

Circulating miRNAs as Noninvasive Biomarkers for PDAC Diagnosis and Prognosis in Mexico

Among malignant neoplasms, pancreatic ductal adenocarcinoma (PDAC) has one of the highest fatality rates due to its late detection. Therefore, it is essential to discover a noninvasive, early, specific, and sensitive diagnostic method. MicroRNAs (miRNAs) are attractive biomarkers because they are ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Álvarez-Hilario, Lissuly Guadalupe, Salmerón-Bárcenas, Eric Genaro, Ávila-López, Pedro Antonio, Hernández-Montes, Georgina, Aréchaga-Ocampo, Elena, Herrera-Goepfert, Roberto, Albores-Saavedra, Jorge, Manzano-Robleda, María del Carmen, Saldívar-Cerón, Héctor Iván, Martínez-Frías, Sandra Paola, Thompson-Bonilla, María Del Rocío, Vargas, Miguel, Hernández-Rivas, Rosaura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607652/ https://www.ncbi.nlm.nih.gov/pubmed/37894871 http://dx.doi.org/10.3390/ijms242015193

Ejemplares similares

H2A.Z overexpression suppresses senescence and chemosensitivity in pancreatic ductal adenocarcinoma
por: Ávila-López, P. A., et al.
Publicado: (2021)

Scaling the immune incline in PDAC
por: Rojas, Luis A., et al.
Publicado: (2021)

Transverse Space Charge Effect During Bunch Compression in PDAC1 and PDAC2 Compressor Ring
por: Franchetti, Giuliano
Publicado: (2000)

The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC
por: Brown, Matthew, et al.
Publicado: (2020)

Loss of FGFR4 promotes the malignant phenotype of PDAC
por: D’Agosto, Sabrina, et al.
Publicado: (2022)

Autophagy is required for PDAC glutamine metabolism
por: Seo, Ju-Won, et al.
Publicado: (2016)

SIRT 1 Overexpression is Associated with Metastasis of Pancreatic Ductal Adenocarcinoma (PDAC) and Promotes Migration and Growth of PDAC Cells
por: Li, Siqin, et al.
Publicado: (2016)

Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment?
por: Papadakos, Stavros P., et al.
Publicado: (2022)

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
por: Le, Kai, et al.
Publicado: (2020)

The Microbiome in PDAC—Vantage Point for Future Therapies?
por: Pfisterer, Nina, et al.
Publicado: (2022)

p21-Activated Kinase 1 Promotes Breast Tumorigenesis via Phosphorylation and Activation of the Calcium/Calmodulin-Dependent Protein Kinase II
por: Saldivar-Cerón, Héctor I., et al.
Publicado: (2022)

(131)I-C19 Iodide Radioisotope and Synthetic I-C19 Compounds as K-Ras4B–PDE6δ Inhibitors: A Novel Approach against Colorectal Cancer—Biological Characterization, Biokinetics and Dosimetry
por: Cruz-Nova, Pedro, et al.
Publicado: (2022)

Combatting PDAC with two tumor-targeting small RNAs
por: Kasinski, Andrea L.
Publicado: (2019)

Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC
por: Digiacomo, Graziana, et al.
Publicado: (2021)

Cell Lineage Infidelity in PDAC Progression and Therapy Resistance
por: Malinova, Antonia, et al.
Publicado: (2021)

Targeting KRAS in PDAC: A New Way to Cure It?
por: He, Qianyu, et al.
Publicado: (2022)

Modifiable Pancreatic Ductal Adenocarcinoma (PDAC) Risk Factors
por: Michalak, Natalia, et al.
Publicado: (2023)

The E6 Oncoprotein of HPV16 AA-c Variant Regulates Cell Migration through the MINCR/miR-28-5p/RAP1B Axis
por: Perez-Bacho, Eduardo Gil, et al.
Publicado: (2022)

Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC
por: Gundlach, Jan-Paul, et al.
Publicado: (2018)

Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC
por: Alhothali, Marwa, et al.
Publicado: (2019)

Upregulated MicroRNA-483-3p is an Early Event in Pancreatic Ductal Adenocarcinoma (PDAC) and as a Powerful Liquid Biopsy Biomarker in PDAC
por: Shao, Huilin, et al.
Publicado: (2021)

Derecho agrario y el juicio de amparo /
por: Bárcenas Chávez, Hilario
Publicado: (2000)

MetastamiRs: Non-Coding MicroRNAs Driving Cancer Invasion and Metastasis
por: Lopez-Camarillo, Cesar, et al.
Publicado: (2012)

PDAC, the Influencer Cancer: Cross-Talk with Tumor Microenvironment and Connected Potential Therapy Strategies
por: Mercanti, Leonardo, et al.
Publicado: (2023)

Immune-related somatic mutation genes are enriched in PDACs with diabetes
por: Wang, Kaixuan, et al.
Publicado: (2019)

AHNAK2 is a potential prognostic biomarker in patients with PDAC
por: Lu, Di, et al.
Publicado: (2017)

Disruption of Broad Epigenetic Domains in PDAC Cells by HAT Inhibitors
por: Gerrard, Diana L., et al.
Publicado: (2019)

SMAD4 Y353C promotes the progression of PDAC
por: Wang, Zusen, et al.
Publicado: (2019)

Cohort Analysis of ADAM8 Expression in the PDAC Tumor Stroma
por: Jaworek, Christian, et al.
Publicado: (2021)

An integrated study to decipher immunosuppressive cellular communication in the PDAC environment
por: AVŞAR, Gülben, et al.
Publicado: (2023)

Mutant SF3B1 promotes malignancy in PDAC
por: Simmler, Patrik, et al.
Publicado: (2023)

Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)
por: Pervin, Jannat, et al.
Publicado: (2023)

Whole-body bioluminescence imaging of T-cell response in PDAC models
por: McMorrow, Roisin, et al.
Publicado: (2023)

NFIC regulates ribosomal biology and ER stress in pancreatic acinar cells and restrains PDAC initiation
por: Cobo, Isidoro, et al.
Publicado: (2023)

ANO1 (TMEM16A) in pancreatic ductal adenocarcinoma (PDAC)
por: Sauter, D. R. P., et al.
Publicado: (2014)

BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC
por: Jauset, Toni, et al.
Publicado: (2018)

Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC
por: Strell, Carina, et al.
Publicado: (2017)

Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies
por: Reyes-Castellanos, Gabriela, et al.
Publicado: (2020)

Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)—basis and current status
por: Ramaswamy, Anant, et al.
Publicado: (2022)

A novel methylation signature predicts inferior outcome of patients with PDAC
por: Gu, Minqi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h3ivdori6fb94dugg9o8k8ehi4